Biomarkers Market Analysis by Industry Growth, Size, Share, Demand, Trends
and Research Report, 2021-2028
The global biomarkers market size was valued at USD 51.18 billion in 2020 and is expected to grow
at a compound annual growth rate (CAGR) of 14.2% from 2021 to 2028. The increasing prevalence
of chronic diseases, advancements in the techniques used for the development of biomarker-based
diagnostics, and the growing geriatric population are the key factors projected to boost the market
growth over the forecast period. The rising number of COVID-19 cases across the globe and an
increasing number of researches on the use of biomarkers for facilitating the detection & treatment of
COVID-19 will also support market growth.
Recent advancements in biomarkers, such as biomarker signatures, are making neurological diseases
more treatable. This has resulted in non-invasive testing, faster drug development, and early
diagnosis. R&D is leading to the discovery of novel biomarkers. For instance, as per Nature Journal
in 2020, tetranectin is a potential biomarker for heart failure diagnosis. Similarly, in 2020, sTNFR2
was revealed as a novel biomarker for the diagnosis of acute adult T-cell leukemia/lymphoma. The
market is likely to witness lucrative growth over the forecast period due to such discoveries and
Key Player Mentioned:
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
Siemens Healthineers AG
To identify the key drivers and the competitors’ insights, Request a Sample @:
Product Segment Analysis:
Application Segment Analysis:
Drug Discovery & Development
Moreover, Amgen announced the launch of the Biomarker Assist program in April 2021 to